Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Pharmaceutical Reports
Yusri, Iskandar
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
In Silico Molecular Docking of Flavonoids from Vitex trifolia L. Leaves as Potential Inhibitors of EGFR Double Mutations Yusri, Iskandar; Fawwaz, Muammar; Olii, Audia Triani
Pharmaceutical Reports Vol 5, No 1 (2026): (March) Pharmaceutical Reports
Publisher : Universitas Muslim Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33096/pharmrep.v5i1.397

Abstract

The Legundi plant (Vitex trifolia L.) is known to contain flavonoid compounds that exhibit potential anticancer activity through the inhibition of cancer cell growth. This study aimed to evaluate the binding affinity of flavonoid compounds from Vitex trifolia L. leaves against the epidermal growth factor receptor (EGFR) with double mutations (L858R/T790M) using a molecular docking approach. An in silico study was conducted by docking flavonoid compounds with the EGFR protein (PDB ID: 3IKA) using the AutoDock Vina program. A total of 14 flavonoid compounds were analyzed to assess their binding affinity and interaction profiles. The docking results revealed that the compound 2-(2,4-dimethoxyphenyl)-7-hydroxy-5-methoxy-2,3-dihydro- 4H-chromen-4-one (C18H18O6) exhibited the lowest binding free energy, indicating the strongest affinity toward the target receptor. Furthermore, the interaction analysis showed that this compound formed multiple types of interactions with the EGFR active site, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions. These findings suggest that flavonoid compounds from Vitex trifolia L. have potential as inhibitors of EGFR double mutations and may serve as promising candidates for further development as anticancer agents.
Co-Authors Audia Triani Olii, Audia Triani Muammar Fawwaz